Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection
- PMID: 9024879
- DOI: 10.1016/s0020-7519(96)00111-7
Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection
Abstract
The N-demethylation of macrolides was studied in a murine model of infection. Mice were infected with a cystogenic strain of Toxoplasma gondii (20 or 40 cysts/mouse) and microsomes were prepared from liver homogenates and jejunum villus tip enterocytes on day 10 post-infection. The rate of N-demethylation of the anti-Toxoplasma macrolides azithromycin, clarithromycin and clindamycin was investigated and compared to that of the macrolide erythromycin, a marker of activity of the cytochrome P-450 3A (CYP3A) mono-oxygenases. In infected mice (20 cysts/mouse), the rate of N-demethylation fell in the liver and jejunum for erythromycin (-25% and -35%, respectively), azithromycin (-12% and -10%, respectively), clarithromycin (-23% and -21%, respectively) and clindamycin (-20% and -28%, respectively). The degree of hepatic depression was more marked in mice receiving a 40-cysts burden: for erythromycin (-54%), azithromycin (-29%), clarithromycin (-49%) and clindamycin (-47%).
Similar articles
-
Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and N(G)-monomethyl-L-arginine on the hepatic suppression.Xenobiotica. 1996 Apr;26(4):381-94. doi: 10.3109/00498259609046717. Xenobiotica. 1996. PMID: 9173679
-
Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.Clin Pharmacol Ther. 1998 Sep;64(3):278-85. doi: 10.1016/S0009-9236(98)90176-X. Clin Pharmacol Ther. 1998. PMID: 9757151 Clinical Trial.
-
Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.Drug Metab Dispos. 1997 May;25(5):623-30. Drug Metab Dispos. 1997. PMID: 9152603
-
Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.Clin Pharmacol Ther. 2001 Oct;70(4):305-10. Clin Pharmacol Ther. 2001. PMID: 11673745 Review. No abstract available.
-
Dental therapeutic indications for the newer long-acting macrolide antibiotics.J Am Dent Assoc. 1999 Sep;130(9):1341-3. doi: 10.14219/jada.archive.1999.0404. J Am Dent Assoc. 1999. PMID: 10492541 Review.
Cited by
-
Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro.ACS Infect Dis. 2018 Aug 10;4(8):1264-1274. doi: 10.1021/acsinfecdis.8b00113. Epub 2018 Jul 25. ACS Infect Dis. 2018. PMID: 29998728 Free PMC article.
-
Proteomic Profiling of Mouse Liver following Acute Toxoplasma gondii Infection.PLoS One. 2016 Mar 22;11(3):e0152022. doi: 10.1371/journal.pone.0152022. eCollection 2016. PLoS One. 2016. PMID: 27003162 Free PMC article.
-
High-Throughput Repurposing Screen Reveals Compounds with Activity against Toxoplasma gondii Bradyzoites.ACS Infect Dis. 2025 Mar 14;11(3):600-609. doi: 10.1021/acsinfecdis.4c00689. Epub 2025 Feb 11. ACS Infect Dis. 2025. PMID: 39933705 Free PMC article.
-
Transcriptomic analysis of mouse liver reveals a potential hepato-enteric pathogenic mechanism in acute Toxoplasma gondii infection.Parasit Vectors. 2016 Aug 3;9(1):427. doi: 10.1186/s13071-016-1716-x. Parasit Vectors. 2016. PMID: 27488578 Free PMC article.
-
High Throughput Repurposing Screen Reveals Compounds with Activity Against Toxoplasma gondii Bradyzoites.bioRxiv [Preprint]. 2024 Aug 22:2024.07.01.601569. doi: 10.1101/2024.07.01.601569. bioRxiv. 2024. Update in: ACS Infect Dis. 2025 Mar 14;11(3):600-609. doi: 10.1021/acsinfecdis.4c00689. PMID: 39005312 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources